LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan FOSTER CITY, Calif. / Mar 27, 2025 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for... Read More

FOSTER CITY, Calif. / Mar 10, 2025 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 17,620 shares of common stock and 9,290 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

2024 net product sales of $336.4 million 2025 expected global net product sales of $420 million to $435 million VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026 CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET FOSTER CITY, Calif. / Feb 26, 2025 /... Read More

CTEXLI is the first and only medication approved for the treatment of CTX in adults Approval based on Phase 3 RESTORE study results CTEXLI granted U.S. FDA Orphan Drug exclusivity for the treatment of CTX FOSTER CITY, Calif. / Feb 24, 2025 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLI™ (chenodiol) tablets, a bile acid, for the... Read More

FOSTER CITY, Calif. / Feb 19, 2025 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2024 financial results on Wednesday, February 26, 2025. Mirum will also host a conference call to discuss the fourth quarter and year-end 2024 financial results and recent corporate progress. Conference call details: Wednesday, February 26, 2025 4:30 p.m. ET / 1:30... Read More

FOSTER CITY, Calif. / Feb 10, 2025 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 49,600 shares of common stock and 24,800 restricted stock units (“RSUs”) to 10 new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate 2025 expected global net product sales of $420 million to $435 million VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 FOSTER CITY, Calif. / Jan 13, 2025 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq:... Read More

FOSTER CITY, Calif. / Jan 10, 2025 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,900 shares of common stock and 26,950 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

FOSTER CITY, Calif. / Dec 10, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 48,400 shares of common stock and 24,200 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis FOSTER CITY, Calif. / Nov 14, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present data at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting®, taking place November 15-19, 2024, in San Diego, California. Enclosed below are the... Read More

Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, interim results to be presented as a Late Breaker presentation at AASLD’s The Liver Meeting® 2024 PDUFA date for chenodiol in CTX is December 28, 2024 In-licensed global rights to PDE4D inhibitor MRM-3379 Conference call to... Read More

FOSTER CITY, Calif. / Nov 08, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 8, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 56,100 shares of common stock and 28,050 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

FOSTER CITY, Calif. / Nov 07, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19 th Company... Read More

FOSTER CITY, Calif. / Nov 04, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter 2024 financial results and recent corporate progress. Conference call details: Tuesday, November 12, 2024 8:30 a.m. ET / 5:30 a.m. PT Dial-in: U.S./Toll-Free: + 1 833... Read More

FOSTER CITY, Calif. / Oct 31, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November 6-9, 2024, in Hollywood, Florida. Data highlighting clinical benefit and real-world evidence for patients with Alagille syndrome (ALGS) and Progressive Familial... Read More

FOSTER CITY, Calif. / Oct 10, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on October 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,100 shares of common stock and 17,050 restricted stock units (“RSUs”) to four new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

Designation based on positive interim analysis of Phase 2b VANTAGE study FOSTER CITY, Calif. / Oct 10, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to volixibat as a potential treatment for cholestatic pruritus in patients with primary biliary cholangitis (PBC). The regulatory designation is... Read More

FOSTER CITY, Calif. / Sep 10, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on September 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 19,700 shares of common stock and 9,850 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

FOSTER CITY, Calif. / Aug 28, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Morgan Stanley 22 nd Annual Global Healthcare Conference Company... Read More

FOSTER CITY, Calif. / Aug 09, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 9, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 59,000 shares of common stock and 29,500 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies LIVMARLI for treatment of PFIC granted marketing authorization in Europe Initiating LIVMARLI EXPAND study for pruritus in rare cholestatic conditions Conference call to provide business updates today, August 7 at 1:30 p.m. PT/4:30... Read More

FOSTER CITY, Calif. / Jul 31, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2024 financial results on August 7, 2024. Mirum will also host a conference call to discuss the second quarter 2024 financial results and recent corporate progress. Conference call details: Wednesday, August 7, 2024 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: +1 833 470... Read More

FOSTER CITY, Calif. / Jul 25, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The expanded label includes use in PFIC patients 12 months and older as well as... Read More

FOSTER CITY, Calif. / Jul 10, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 40,800 shares of common stock and 20,400 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older. Approval follows positive opinion from CHMP concluding LIVMARLI’s clinical benefit over existing therapy in PFIC. LIVMARLI also received positive COMP opinion recommending maintenance of Orphan Drug Designation in PFIC. FOSTER CITY, Calif. / Jul 08, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. ( Nasdaq:... Read More

Submission based on the positive Phase 3 RESTORE study Mirum holds orphan designation for chenodiol in CTX Potential to have first and only therapy indicated for CTX in the US FOSTER CITY, Calif. / Jun 28, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the submission of a new drug application (NDA) for chenodiol for the treatment of patients in the U.S. with cerebrotendinous xanthomatosis... Read More

- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus - VISTAS PSC interim analysis exceeds efficacy threshold for study continuation - Mirum to host conference call to discuss analyses, today, June 17 at 8:30 a.m. ET/5:30 a.m. PT FOSTER CITY, Calif. / Jun 17, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM)... Read More

FOSTER CITY, Calif. / Jun 16, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC). Conference call details: Monday June 17, 2024 8:30... Read More

FOSTER CITY, Calif. / Jun 10, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on June 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 56,600 shares of common stock and 28,300 restricted stock units (“RSUs”) to 14 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee... Read More

Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome Long-term extension data from LIVMARLI PFIC studies highlight improvement in key liver markers and growth FOSTER CITY, Calif. / Jun 06, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from new analyses showing long-term treatment with LIVMARLI were presented... Read More

FOSTER CITY, Calif. / Jun 05, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Wednesday, June 12 th at 10:00 AM EDT. Visit the... Read More

Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo across all PFIC types studied. CHMP assessment concluded that LIVMARLI in PFIC brings significant clinical benefit over the existing approved therapy. Additionally, LIVMARLI received favorable COMP opinion recommending maintenance of Orphan Drug Designation in... Read More

Data showcases sustained clinical benefit following 7 years of LIVMARLI treatment in patients with Alagille syndrome Long-term extension data from LIVMARLI PFIC studies highlight improvement in key liver markers and growth FOSTER CITY, Calif. / May 29, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that new analyses from long-term treatment with LIVMARLI will be presented at the European... Read More

Seven abstracts highlighting ALGS and PFIC data, including three oral presentations Long-term extension data from Phase 3 MARCH-ON PFIC study presented at plenary session and selected among the highest scoring abstracts FOSTER CITY, Calif. / May 18, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the 56 th European Society for Paediatric, Gastroenterology, Hepatology,... Read More

FOSTER CITY, Calif. / May 10, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300 restricted stock units (“RSUs”) to 11 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee... Read More

First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March Volixibat VISTAS and VANTAGE interim analyses scheduled for June of 2024 Cash balance of $302.8 million as of March 31, 2024 Conference call to provide business updates today, May 8 at 1:30 p.m. PT/4:30 p.m. ET FOSTER CITY,... Read More

FOSTER CITY, Calif. / May 07, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the Citizens JMP Life Sciences Conference in New York, NY on Tuesday, May 14 th at 1:30 PM EDT. Visit the Investors and... Read More

Data demonstrate significant benefit across broadest range of genetic PFIC types ever studied Significant improvements observed across multiple parameters including pruritus, serum bile acids, growth and bilirubin FOSTER CITY, Calif. / May 07, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from the Phase 3 MARCH-PFIC study evaluating LIVMARLI® (maralixibat) oral solution in... Read More

FOSTER CITY, Calif. / May 01, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a conference call to discuss the first quarter 2024 financial results and recent corporate progress. Conference call details: Wednesday, May 8, 2024 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: +1 833 470 1428... Read More

FOSTER CITY, Calif. / Apr 10, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 36,100 shares of common stock and 18,050 restricted stock units (“RSUs”) to nine new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder LIVMARLI is the first and only approved medication to treat cholestatic pruritus in patients with Alagille syndrome in Canada FOSTER CITY, Calif. / Apr 02, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the Canadian Agency for... Read More

FDA approval based on MARCH Phase 3 study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo Label covers broad range of PFIC subtypes Immediate launch and availability for eligible patients in the U.S. FOSTER CITY, Calif. / Mar 13, 2024 / Business Wire / Mirum... Read More

FOSTER CITY, Calif. / Mar 08, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 8, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 27,200 shares of common stock and 13,600 restricted stock units (“RSUs”) to six new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee... Read More

FOSTER CITY, Calif. / Mar 05, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Leerink Partners Global Biopharma Conference 2024 on Tuesday March 12,... Read More

Results demonstrate 70% risk reduction for long-term clinical outcomes in patients with Alagille syndrome (ALGS) treated with LIVMARLI (p<0.0001) Data are the first to demonstrate a six-year transplant-free survival benefit in patients with ALGS using a pharmacological interventional therapy FOSTER CITY, Calif. / Feb 29, 2024 / Business Wire / Mirum Pharmaceuticals, Inc . (Nasdaq: MIRM) today announced that Hepatology... Read More

Net product sales totaled $178.9 million, and full year 2023 revenue totaled $186.4 million, delivering 142% growth over 2022 total revenue 2024 expected global net product sales of $310 million to $320 million LIVMARLI PFIC PDUFA date on track for March 13, 2024 Volixibat VISTAS and VANTAGE interim analyses expected in first half of 2024 Conference call to provide business updates today, February 28 at 1:30 p.m. PT/4:30... Read More

FOSTER CITY, Calif. / Feb 21, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2023 financial results on Wednesday, February 28, 2024. Mirum will also host a conference call to discuss the fourth quarter and year-end 2023 financial results and recent corporate progress. Conference call details: Wednesday, February 28, 2024 4:30 p.m. ET / 1:30... Read More

FOSTER CITY, Calif. / Feb 09, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 9, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 33,200 shares of common stock and 16,610 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

FOSTER CITY, Calif. / Jan 19, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that in conjunction with the recent appointment of Joanne Quan, MD as Chief Medical Officer, the Compensation Committee of Mirum’s Board of Directors approved an inducement grant of non-qualified stock options to purchase 75,000 shares of common stock and 37,500 restricted stock units (“RSUs”) under Mirum’s 2020... Read More

FOSTER CITY, Calif. / Jan 16, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical development, clinical operations, and safety programs for Mirum’s pipeline of programs addressing rare diseases. Dr. Quan was most recently Chief Medical Officer at Nuvig Therapeutics. Prior to Nuvig, she served in... Read More

FOSTER CITY, Calif. / Jan 10, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 50,950 shares of common stock and 25,480 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

$186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited LIVMARLI net products sales of $141-143 million expected for 2023, representing approximately 89% year-over-year growth, preliminary and unaudited FOSTER CITY, Calif. / Jan 08, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided its preliminary and unaudited estimates for... Read More

FOSTER CITY, Calif. / Jan 03, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 10:30 a.m. PT.... Read More

Study did not meet primary or secondary endpoints. LIVMARLI was generally well-tolerated, with no new safety findings. FOSTER CITY, Calif. / Dec 18, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced top-line results of the Phase 2 EMBARK study evaluating LIVMARLI® (maralixibat) oral solution versus placebo given as an adjuvant therapy to Kasai surgery in patients with biliary atresia. The... Read More

FOSTER CITY, Calif. / Dec 08, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 8, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,750 shares of common stock and 12,880 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

FOSTER CITY, Calif. / Nov 20, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it is scheduled to present at the 6 th annual Evercore ISI HealthCONx Conference on Tuesday, November 28 th 2023 at 3:25 pm ET, as well as 1x1... Read More

Late-breaking poster presentation features LIVMARLI® data showing long-term maintenance of response in patients with PFIC Four poster presentations highlight LIVMARLI PFIC data as well as a poster with proof-of-concept trial data from volixibat study in intrahepatic cholestasis of pregnancy FOSTER CITY, Calif. / Nov 13, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its... Read More

FOSTER CITY, Calif. / Nov 10, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 20,000 shares of common stock and 10,000 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

FOSTER CITY, Calif. / Nov 03, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it is scheduled to participate in a fireside chat at the 2023 UBS Biopharma Conference on Wednesday, November 8 th 2023 at 2:00 pm ET, as well... Read More

Third quarter 2023 total revenue of $47.7 million Completed acquisition of CHENODAL® and CHOLBAM® Announced positive Phase 3 RESTORE study results evaluating CHENODAL (chenodiol) in patients with CTX; NDA filing expected in H1 2024 Conference call to provide business updates today, November 2 at 1:30 p.m. PT/4:30 p.m. ET FOSTER CITY, Calif. / Nov 02, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today... Read More

Late-breaker poster presentation accepted featuring LIVMARLI® data showing long-term maintenance of response in patients with PFIC Four poster presentations will highlight LIVMARLI PFIC data and volixibat proof-of-concept trial data in intrahepatic cholestasis of pregnancy FOSTER CITY, Calif. / Oct 30, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that data from its LIVMARLI and volixibat... Read More

FOSTER CITY, Calif. / Oct 27, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2023 financial results on Thursday, November 2 nd , 2023. Mirum will also host a conference call to discuss the third quarter 2023 financial results and recent corporate progress. Conference call details: Thursday, November 2 nd , 2023 4:30 p.m. ET / 1:30 p.m. PT Dial-in:... Read More

FOSTER CITY, Calif. / Oct 17, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the Supplemental New Drug Application (sNDA) for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The new Prescription Drug User Fee Act... Read More

FOSTER CITY, Calif. / Oct 10, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on October 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 92,050 shares of common stock and 46,030 restricted stock units (“RSUs”) to 12 new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

- LIVMARLI PFIC primary analysis from MARCH study awarded prestigious Gerard Odell Prize for Excellence in Pediatric Hepatology Research 15 abstracts demonstrating robust clinical findings from LIVMARLI studies and real-world experience in ALGS and PFIC FOSTER CITY, Calif. / Oct 07, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the presentation of a series of analyses demonstrating further... Read More

Primary endpoint met (p<0.0001); 20-fold difference in urine bile alcohols First and only prospective, controlled clinical trial in CTX Plasma cholestanol endpoint met (p=0.0083), the driver of poor outcomes in CTX patients Data to be submitted for presentation at future medical congress Mirum plans to file an NDA with the U.S. FDA in the first half of 2024 FOSTER CITY, Calif. / Oct 02, 2023 / Business Wire / Mirum... Read More

15 abstracts accepted for presentation showcasing LIVMARLI data from ALGS and PFIC programs LIVMARLI PFIC primary analysis from MARCH study awarded prestigious Gerard Odell Prize for Excellence in Pediatric Hepatology Research FOSTER CITY, Calif. / Sep 26, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that data from its LIVMARLI ® (maralixibat) oral solution studies as well as data from... Read More

FOSTER CITY, Calif. / Sep 21, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it is scheduled to participate in a fireside chat at the 2023 Cantor Global Healthcare Conference on Thursday, September 28 th 2023 at 11:30... Read More

FOSTER CITY, Calif. / Sep 11, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Eric Bjerkholt as chief financial officer (CFO). “Eric is an accomplished CFO bringing an outstanding track record in driving financial performance, business development, and operations management,” said Chris Peetz, president and chief executive officer at Mirum. “Eric is joining at an important... Read More

FOSTER CITY, Calif. / Sep 08, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on September 8, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 174,000 shares of common stock and 91,000 restricted stock units (“RSUs”) to 21 new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

FOSTER CITY, Calif. / Sep 06, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: H.C. Wainwright’s 25 th Annual Global Investment Conference: September 11... Read More

Mirum has acquired Travere’s rights and assets related to Cholbam® and Chenodal® Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments Expands Mirum’s leadership in rare liver disease with two additional commercial products and a near-term Phase 3 label expansion opportunity Advances Travere’s strategy to deliver new treatment standards from its pipeline... Read More

FOSTER CITY, Calif. / Aug 10, 2023 / Business Wire / Mirum Pharmaceuticals, Inc . (Nasdaq: MIRM) today announced that on August 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,200 shares of common stock and 17,100 restricted stock units (“RSUs”) to six new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

$37.5 million total revenue, including net product sales for LIVMARLI ® (maralixibat) oral solution of $32.5 million, for second quarter 2023 Acquiring CHENODAL ® and CHOLBAM ® , advancing Mirum’s leadership in pediatric hepatology with a multi-product franchise Four late-stage clinical trial data readouts expected later this year Conference call to provide business updates today, August 3 at 1:30 p.m. PT/4:30 p.m. ET FOSTER... Read More

FOSTER CITY, Calif. / Jul 27, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2023 financial results on Thursday, August 3, 2023. Mirum will also host a conference call to discuss the second quarter 2023 financial results and recent corporate progress. Conference call details: Thursday, August 3, 2023 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: +1... Read More

First and only medication authorized in Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome. Approval supported by more than six years of LIVMARLI data demonstrating improvements in pruritus and serum bile acids. Data from LIVMARLI clinical trials published in The Lancet and Hepatology FOSTER... Read More

Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal® Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones Mirum announces concurrent private placement of $210 million, funding upfront payment Expands Mirum’s leadership in rare liver disease with two commercial products and a near-term Phase 3 label expansion opportunity... Read More

FOSTER CITY, Calif. / Jul 10, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 44,850 shares of common stock and 22,430 restricted stock units (“RSUs”) to ten new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee... Read More

New analysis demonstrates bilirubin normalization in PFIC patients treated with LIVMARLI (maralixibat); the only IBAT inhibitor reported to show this effect Sleep improvement observed in patients with PFIC correlated with maralixibat-driven pruritus reduction (selected as Best of EASL) Maralixibat demonstrates efficacy and maintenance of response in patients with ALGS who transition to adulthood FOSTER CITY, Calif. / Jun 23,... Read More

Improvement in pruritus, serum bile acid levels and bilirubin were highly predictive of six-year event-free and transplant-free survival in patients with cholestatic pruritus in Alagille syndrome treated with LIVMARLI Analysis highlights for the first-time potential markers associated with better outcomes to help drive clinical care in patients with Alagille syndrome FOSTER CITY, Calif. / Jun 14, 2023 / Business Wire / Mirum... Read More

FOSTER CITY, Calif. / Jun 09, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 9, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 43,150 shares of common stock and 22,030 restricted stock units (“RSUs”) to nine new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee... Read More

Five abstracts accepted for presentation, including data demonstrating bilirubin normalization with LIVMARLI in PFIC Sleep improvement data from MARCH-PFIC study included among ‘Best of EASL’ presentations Maintenance of response in patients with PFIC selected as late-breaker presentation FOSTER CITY, Calif. / Jun 07, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present data... Read More

Seven oral and poster presentations highlighted during meeting Phase 3 MARCH PFIC data selected as one of highest scoring abstracts and presented during the plenary session RISE study evaluating LIVMARLI in infants with ALGS and PFIC included among highest scoring posters FOSTER CITY, Calif. / May 19, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the 55 th European... Read More

First and only data evaluating IBAT inhibition in treating primary sclerosing cholangitis (PSC) Data provided proof-of-concept for Phase 2b VISTAS study evaluating volixibat, an IBAT inhibitor, in patients with PSC FOSTER CITY, Calif. / May 18, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Hepatology Communications published data from the CAMEO study evaluating the safety,... Read More

Seven abstracts accepted including four oral presentations Phase 3 MARCH PFIC data selected as one of highest scoring abstracts and will be presented during the plenary session on May 18 RISE study evaluating LIVMARLI in infants with ALGS or PFIC included among highest scoring posters FOSTER CITY, Calif. / May 17, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present data at... Read More

Topline data are expected in second half of 2023. EMBARK will be the first completed randomized study of an IBAT inhibitor for the treatment of biliary atresia. FOSTER CITY, Calif. / May 11, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced it has completed enrollment of its Phase 2b EMBARK study for pediatric patients with biliary atresia, the most common indication for pediatric liver... Read More

FOSTER CITY, Calif. / May 10, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 20,850 shares of common stock and 10,430 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee... Read More

$31.6 million total revenue, including net product sales for LIVMARLI ® (maralixibat) oral solution of $29.1 million, for first quarter 2023 Conference call to provide business updates today, May 4 at 1:30 p.m. PT/4:30 p.m. ET FOSTER CITY, Calif. / May 04, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update. “We began 2023... Read More

FOSTER CITY, Calif. / Apr 27, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first quarter 2023 financial results and recent corporate progress. Conference call details: Thursday, May 4, 2023 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: 1 833 470... Read More

FOSTER CITY, Calif. / Apr 13, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was... Read More

FOSTER CITY, Calif. / Apr 12, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced estimated revenue, including net product sales, and cash balance for the first quarter 2023. The company’s preliminary unaudited financial results for the first quarter of 2023 include: Approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and approximately... Read More

FOSTER CITY, Calif. / Apr 12, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).... Read More

FOSTER CITY, Calif. / Apr 10, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,950 shares of common stock and 12,960 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

FOSTER CITY, Calif. / Apr 06, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Tim Walbert has been appointed to the company’s Board of Directors. In addition to Mr. Walbert’s appointment, the company shared that Niall O’Donnell, Ph.D., a Mirum director since November 2018, has announced his plan to step down from the Board of Directors concurrent with the upcoming 2023 Annual Meeting of... Read More

Marketing Authorization variation submitted for treatment of patients with progressive familial intrahepatic cholestasis (PFIC) two months of age and older; data supports treatment across the broadest range of genetic types ever studied. Application based on statistically significant and clinically meaningful improvements in serum bile acids, pruritus, bilirubin, and growth from the Phase 3 MARCH study. Supplemental new drug... Read More

FOSTER CITY, Calif. / Mar 14, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a reduction in age from one year to three months for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The label expansion was based on data from the RISE study which characterized... Read More

FOSTER CITY, Calif. / Mar 10, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 40,050 shares of common stock and 20,050 restricted stock units (“RSUs”) to four new employees under Mirum’s 2020 Inducement Plan. The Compensation... Read More

FOSTER CITY, Calif. / Mar 08, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2022 and provided a business update. “We are proud of our strong commercial, clinical and regulatory execution in 2022 that realized $75.1 million in LIVMARLI net product sales in the first full fiscal year of our U.S. launch and groundbreaking clinical data for... Read More

FOSTER CITY, Calif. / Mar 01, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2022 financial results on Wednesday, March 8, 2023. Mirum will also host a conference call to discuss the fourth quarter and year-end 2022 financial results and recent corporate progress. Conference call details: Wednesday, March 8, 2023 4:30 p.m. ET / 1:30 p.m. PT... Read More

FOSTER CITY, Calif. / Feb 14, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has submitted a supplemental New Drug Application (sNDA) for LIVMARLI ® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC). The sNDA submission is based on data from the MARCH PFIC Phase 3... Read More

FOSTER CITY, Calif. / Feb 10, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 5,000 shares of common stock and 2,500 restricted stock units (“RSUs”) to one new employee under Mirum’s 2020 Inducement Plan. The Compensation... Read More

FOSTER CITY, Calif. / Feb 09, 2023 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the SVB Securities Global Biopharma Conference: Company presentation Wednesday, February 15, starting at 5:00 p.m. ET... Read More

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 23,900 shares of common stock and 12,000 restricted stock units (“RSUs”) to four new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the... Read More

$76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited sNDA for LIVMARLI in PFIC submission planned for first quarter 2023 Multiple data analyses planned in 2023 advancing late-stage cholestasis programs Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided a preview of the company’s plans, estimated revenue and net product sales for Q4 and full year... Read More

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023. Presentation and Q&A Session Location: San Francisco, CA Date: Tuesday, January 10, 2023 Time:... Read More

FOSTER CITY, Calif.--( BUSINESS WIRE )-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022. Company presentation... Read More